Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

pharmachim ab - merkaptopurinmonohydrat - tablett - 50 mg - laktosmonohydrat hjälpämne; merkaptopurinmonohydrat 50 mg aktiv substans - merkaptopurin

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

orifarm ab - merkaptopurinmonohydrat - tablett - 50 mg - merkaptopurinmonohydrat 50 mg aktiv substans; laktosmonohydrat hjälpämne - merkaptopurin

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

orifarm ab - merkaptopurinmonohydrat - tablett - 50 mg - laktosmonohydrat hjälpämne; merkaptopurinmonohydrat 50 mg aktiv substans - merkaptopurin

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - merkaptopurinmonohydrat - tablett - 50 mg - laktosmonohydrat hjälpämne; merkaptopurinmonohydrat 50 mg aktiv substans - merkaptopurin

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - gall- och leverterapi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 och 5.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multipelt myelom - antineoplastiska medel - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multipel skleros, skovvis förlöpande - immunsuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

mylan s.a.s. - risperidon - munsönderfallande tablett - 3 mg - risperidon 3 mg aktiv substans; aspartam hjälpämne; mannitol hjälpämne - risperidon

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

mylan s.a.s. - risperidon - munsönderfallande tablett - 4 mg - aspartam hjälpämne; risperidon 4 mg aktiv substans; mannitol hjälpämne - risperidon